Prolor Biotech releases human growth hormone Phase 2 trial results
The objective of the trial is to measure the safety and tolerability of hGH-CTP and to assess dose ranging and dose response. The trial is enrolling up to
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).